Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases

This is a single-institution, phase 2 trial of zanzalintinib plus investigator-choice bone-strengthening agent in patients with metastatic renal cell carcinoma (RCC) with bone metastases whose disease has advanced on 1-3 prior lines of therapy, including at least one immune oncology-based (IO) therapy in the adjuvant or first-line metastatic setting.

Trial Details

NCT ID
NCT07043608
Phase
PHASE2
Sponsor
Kelly Fitzgerald, MD
Status
RECRUITING
Cancer Type
Kidney Cancer
Interventions
  • Zanzalintinib
  • Investigator Choice of Bone Strengthening Agents (BSA)
  • Non-Investigational Radiation Therapy (RT)
  • Bone Scan
  • Computerized tomography (CT) Scan
Locations (sample)
  • San Francisco, California, United States|37.77493,-122.41942

Key Eligibility Criteria

  • Participants must have unresectable advanced or metastatic RCC with a predominant clear cell histologic component .
  • At least three bone metastases are present and detectable on bone scan, and at least one bone metastasis is NOT planned to be treated with radiatio…
  • Previously treated with 1-3 prior lines of therapy in at least one of the following settings:
  • Metastatic setting; must have received combination therapy containing either programmed cell death protein 1 (PD-1) inhibitor/cytotoxic T-lymphocyt…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Kidney Cancer Trials on Trialify →